Hosted on MSN
Goldman Sachs Initiates Coverage of iRhythm Technologies (IRTC) with Neutral Recommendation
Fintel reports that on October 4, 2024, Goldman Sachs initiated coverage of iRhythm Technologies (NasdaqGS:IRTC) with a Neutral recommendation. Analyst Price Forecast Suggests 94.05% Upside As of ...
iRhythm hit with FDA warning letter over alleged regulatory 'nonconformities' in heart monitor patch
A recent warning letter from the FDA may have iRhythm Technologies changing its tune. The remote monitoring tech maker disclosed its receipt of the letter in a filing (PDF) with the U.S. Securities ...
Provides Evidence From Interpreting Legal Filings That the Department of Justice Is Investigating a Possible Cover-up by iRhythm Management Related to Potentially Fatal Product Flaws Raises Serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback